## Edgar Filing: ISTA PHARMACEUTICALS INC - Form DFAN14A

ISTA PHARMACEUTICALS INC Form DFAN14A April 24, 2012

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## SCHEDULE 14A (Rule 14a-101)

## INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

	Filed by the Registrant "	Filed by a Party other than the Registrant x	
Check the appropriate box:			
•		Preliminary Proxy Statement	
••	Confidential, For Use o	f the Commission Only (as permitted by Rule 14a-6(e)(2))	
•		Definitive Proxy Statement	
		Definitive Additional Materials	
х	Sol	citing Material Pursuant to §240.14a-12	
ISTA PHARMACEUTICALS, INC.			
(Name of Registrant as Specified in Its Charter)			
BAUSCH & LOMB INCORPORATED			
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)			
Payment of I	Filing Fee (Check the approp	riate box):	
X		No fee required.	
••	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	(1) Ti	tle of each class of securities to which transaction applies:	

(2) Aggregate number of securities to which transaction applies:

## Edgar Filing: ISTA PHARMACEUTICALS INC - Form DFAN14A

(3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

Fee paid previously with preliminary materials:

"Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(1) Amount previously paid:

(2)Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

..

# Press Release

This filing consists of the press release issued by ISTA and Bausch & Lomb, attached to the Current Report filed by ISTA on Form 8-K dated April 24, 2012, as Exhibit 99.1 and incorporated herein by reference.